The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.
Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.
/Cencora%20Inc_%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Cencora has consistently outperformed the broader market over the past year, and analysts are maintaining a strongly bullish outlook on the company’s growth and earnings potential.
/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
AbbVie has lagged the broader market over the past year, although Wall Street analysts remain moderately optimistic about the company’s long-term growth prospects and pipeline strength.
/Cencora%20Inc_%20chart%20on%20phone-by%20T_Schneider%20via%20Shutterstock.jpg)
Cencora has consistently outperformed the broader market over the past year, and analysts are maintaining a strongly bullish outlook on the company’s growth and earnings potential.
Pharma distributor Cencora has continued to outpace the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver disease....
Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.
Eli Lilly and Company LLY reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines, driven by strong demand for its blockbuster weight loss and diabetes drugs....
Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...